Adoptive Cell Therapy for Cancer
Trial Summary
What is the purpose of this trial?
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial investigator for guidance based on your medical history.
What makes GSK adoptive cell therapy unique compared to other cancer treatments?
GSK adoptive cell therapy is unique because it uses genetically engineered T-cells that specifically target the NY-ESO-1 antigen, which is found in certain cancers like synovial sarcoma and melanoma. This approach allows for precise targeting of cancer cells, potentially leading to better outcomes with fewer side effects compared to traditional treatments.12345
Research Team
Adaptimmune
Principal Investigator
Adaptimmune
Eligibility Criteria
This trial is for people who have previously received GSK adoptive cell therapy as a treatment for tumors. They should be able to consent, have finished or withdrawn from a related GSK study, or completed treatment through managed access. Participants must follow local contraception guidelines and have taken at least one dose of the therapy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ADP adoptive cell therapy
Long-term Follow-up
Participants are monitored for safety following last adoptive cell therapy infusion
Treatment Details
Interventions
- GSK adoptive cell therapy
GSK adoptive cell therapy is already approved in European Union, United States for the following indications:
- Synovial sarcoma
- Synovial sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Adaptimmune
Lead Sponsor
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School